Long-term male-specific chronic pain via telomere- and p53mediated spinal cord cellular senescence
Privacy Notice for California Residents Last updated: February 10, 2026 Privacy Statement - California THIS PRIVACY NOTICE IS APPLICABLE TO CALIFORNIA RESIDENTS ("consumers" or "you") ONLY and supplements the information in Modern Metabolic Medicine's JoinEm general Privacy Statement
If urinary C-peptide:creatinine ratio is used, a value 200 pmol/l [36,37,38]
Whilst gout flare-ups are not listed as a recognised adverse effect in the Summary of Product Characteristics, some patients have reported joint symptoms during treatment
It can affect different parts of the body, including the face, arms, legs, and abdomen, leading to changes in body shape and appearance
Trial design: 2,339 participants Adults with obesity or overweight + at least one weight-related complication Participants did NOT have diabetes Randomized to placebo or retatrutide 4 mg, 9 mg or 12 mg 80-week double-blind trial Pre-specified extension to 104 weeks in participants with BMI 35 Weight loss results at 80 weeks: 4 mg: -19.0% (~47 lbs / 21.4 kg) 9 mg: -25.9% (~64 lbs / 29.2 kg) 12 mg: -28.3% (~70 lbs / 31.9 kg) That degree of weight loss approaches levels traditionally associated with bariatric surgery
:max_bytes(150000):strip_icc()/how-to-select-the-correct-needle-size-for-an-injection-2616536-FINAL-f42600395a324d71b8b3fc4f13f5723d.png)
